Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06251323 · ClinicalTrials.gov registry record · NA
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
A NA study of Diabetes Mellitus, Type 2, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 119,680
- Enrollment target
- 4
- Study locations
NCT06251323 is a NA study of Diabetes Mellitus, Type 2 that is actively recruiting participants, run by Stanford University. The registered enrollment target is 119,680 participants, above the 4,141-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (2790% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT06251323, a NA study of Diabetes Mellitus, Type 2, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 119,680 participants
- Enrollment target
- 4
- Study locations
Study Summary
Sixteen institutions will be selected from a HRSA uniform data system and have data collected for up to 3 years. Eight institutions will begin the iPATH practice transformation during year one, the other eight institutions will begin iPATH in year two. FQHC administrators, clinicians and staff will be enrolled to participate in the iPATH transformation in their clinic and will participate in qualitative interviews. Patient HbA1c data from the clinics will be collected for comparative data analysis during each year of the study.
Conditions Studied
Interventions
- OTHER iPATH implementation approach
Study Locations (4)
California
- Board of Trustees of the Leland Stanford Junior University - Stanford
Massachusetts
- President and Fellows of Harvard College, T.H. Chan School - Boston
Ohio
- The Ohio State University - Columbus
Puerto Rico
- Impactivo, LLC. - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119,680 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06251323
The ClinicalTrials.gov registry entry for NCT06251323 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 119,680 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,141-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (2790% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which iPATH implementation approach is the first listed.
NCT06251323 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT06251323 about?
NCT06251323 is a clinical study titled "Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)". Sixteen institutions will be selected from a HRSA uniform data system and have data collected for up to 3 years. Eight institutions will begin the iPATH practice transformation during year one, the other eight institutions will begin iPATH in year two. FQHC administrators, clinicians and staff will ...
What is the current status of trial NCT06251323?
This trial is currently recruiting. It is a NA study. The enrollment target is 119,680 participants. The study started on 2025-09-30. Estimated completion is 2028-01-31.
What conditions does trial NCT06251323 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT06251323?
The interventions under investigation include: iPATH implementation approach (OTHER).
Who is sponsoring clinical trial NCT06251323?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06251323 being conducted?
This trial has 4 study locations across California, Massachusetts, Ohio, Puerto Rico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.